Press release 📈 Stocks 🌍 China

CARsgen Reports 83% Response Rate in Early CT1182 In Vivo CAR-T Trial

CARsgen's CT1182 shows encouraging early efficacy with 3 complete responses and 2 partial responses in 6 patients, maintaining a favorable safety profile with no treatment-related SAEs.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: 2171.HK ↑ 4/10 (60% confidence).

📊 Affected Assets (1)

2171.HK
Bullish 🤖 60%
📅 Short-term 🌍 CN · Explicit

First clinical data for CT1182 show 3 of 6 patients achieving complete response and 2 partial responses, all ongoing as of the October 31, 2026 cut-off, with no dose-limiting toxicities and only Grade 1 CRS. Positive early efficacy with a favorable safety profile supports the pipeline's value, though the sample is small and the registrational trial filing is only expected in H1 2027.

Catalysts
  • ▲ First clinical data for CT1182: 3 CRs and 2 PRs among 6 efficacy-evaluable patients, all responses ongoing as of October 31, 2026
  • ▲ No DLTs, no treatment-related SAEs, only Grade 1 CRS observed in DLT-evaluable patients
Risk Factors
  • ▼ Only six patients enrolled with a median follow-up of about 3.2 months; data are preliminary
  • ▼ No effective CAR-T expansion in one TCE-refractory patient due to T cell exhaustion and CD20 antigen loss

🧭 Full analysis of these assets

🎯 Key Takeaways

  • Five of six efficacy-evaluable patients achieved a response, with three complete responses and two partial responses as of October 31, 2026.
  • The trial reported no dose-limiting toxicities or treatment-related serious adverse events, with only Grade 1 cytokine release syndrome observed.
  • Patients in the study had a median of 3 prior lines of therapy and a median total tumor burden of 1,927.5 mm².
  • CARsgen expects to file for a registrational clinical trial for CT1182 in the first half of 2027.

📝 Executive Summary

CARsgen Therapeutics released preliminary clinical data for its in vivo CAR-T candidate, CT1182, showing 5 of 6 patients with R/R B-NHL achieved a response. As of October 31, 2026, the trial reported no dose-limiting toxicities and only Grade 1 CRS, supporting the potential for outpatient administration. The company plans to file for a registrational clinical trial in the first half of 2027.

❓ FAQ

When will larger trial data be available?

The company plans further dose exploration to identify the recommended Phase 2 dose and expects to file for a registrational clinical trial in the first half of 2027.